Ensign Peak Advisors
VTYX

Ensign Peak Advisors’s Ventyx Biosciences VTYX Stock Holding History

Ensign Peak Advisors’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-101,175
Closed -$250K – 1753
2023
Q4 		$250K Hold
101,175
– – ﹤0.01% 1714
2023
Q3 		$3.51M Hold
101,175
– – 0.01% 666
2023
Q2 		$3.32M Hold
101,175
– – 0.01% 705
2023
Q1 		$3.39M Buy
+101,175
New +$3.93M 0.01% 668

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ensign Peak Advisors's VTYX Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Ventyx Biosciences (VTYX) in Q1 2024, closing a stake of 101,175 shares — an estimated $250K sold.

Ensign Peak Advisors first reported a position in VTYX in Q1 2023 and held it in 4 quarters. The position peaked at $3.51M in Q3 2023. 126 funds tracked by Wall St. Rank hold VTYX as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Ventyx Biosciences position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 101,175 Ventyx Biosciences shares in Q1 2024, an estimated $250K.
  • Ensign Peak Advisors first reported a position in Ventyx Biosciences in Q1 2023 and held it in 4 quarters.
  • Ensign Peak Advisors's Ventyx Biosciences position peaked at $3.51M in Q3 2023.
  • 126 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.